

Lori Farrar,
Technology Appraisal Project Manager,
**Clopidogrel and modified-release dipyridamole for the prevention of
occlusive vascular events (review of Technology Appraisal No. 90)
Assessment Report**
lori.farrar@nice.org.uk

8th June

Dear Lori,

About Diabetes UK

Diabetes UK is the largest organisation in the UK working for people with diabetes, funding research, campaigning and helping people live with the condition. Our mission is to improve the lives of people with diabetes and to work towards a future without diabetes.

Consultation Response

Diabetes UK is seeking clarification regarding whether it was possible to examine the evidence base specifically with regard to people with diabetes. While we recognise that this was not formally identified within the scope, people with diabetes formed an identified subgroup within the four trials examined by the Assessment Group, and as identified at the submission stage, people with diabetes are considered a high risk group, as once they have established CVD they are at increased risk of further occlusive vascular events. A review of this evidence could impact upon the conclusions of the Assessment Group with regard to people with diabetes specifically.

Whereas the Assessment Group report considers intolerances to medications, contraindications also form an important part of decision making. Some contraindications that may be of particular relevance for people with diabetes were highlighted at the submission stage. Ultimately decisions about the most optimal antiplatelet therapy will need to be tailored to individual clinical need, suitability and choice, and consider safety, contraindications, efficacy, risks, benefits and quality of life considerations.

Yours sincerely


Diabetes UK
